TaperCommunity
Akathisia from antidepressant withdrawal is one of the most distressing and least discussed symptoms people encounter when they stop or reduce their medication. It shows up as a relentless inner restlessness, an almost unbearable compulsion to keep moving, that is distinct from ordinary anxiety and often goes unrecognized by clinicians. Understanding what akathisia is, how withdrawal triggers it, and how to manage it can make the difference between suffering through it blindly and navigating it with a plan.
The word "akathisia" comes from Greek meaning "not sitting." It is a neurological and subjective state in which the person feels an urgent, irresistible need to move, usually in the legs, but sometimes involving the whole body. The feeling is internal rather than purely physical. People describe it as crawling sensations inside the limbs, a kind of agitation that pacing temporarily relieves but never fully resolves.
Akathisia was first described in the context of antipsychotic medications, which block dopamine receptors and can produce severe movement-related side effects. But it is now well-documented in both antidepressant use and antidepressant withdrawal. The Barnes Akathisia Rating Scale, developed by Thomas Barnes in 1989 and still widely used in research, distinguishes objective akathisia (visible restlessness such as shifting weight, rocking, pacing) from subjective akathisia (the inner urge itself). Both forms can occur in withdrawal.
What makes withdrawal akathisia particularly difficult is that it is often invisible to observers. Someone sitting still can be experiencing profound inner torment. The absence of outward movement does not mean the person is comfortable. This invisibility leads to underreporting and underdiagnosis, as clinicians may not think to ask the right questions.
Akathisia is not a character flaw, a mental health crisis, or evidence that someone "can't handle" stopping their medication. It is a physiological response to neurological changes. Recognizing it for what it is represents the first step toward managing it effectively.
Most antidepressants work by increasing serotonin availability in synapses, typically by blocking reuptake (SSRIs and SNRIs). After prolonged use, the brain adapts to higher serotonin levels by downregulating serotonin receptors and changing how those receptors respond to stimulation. When the medication is reduced or stopped, serotonin availability drops sharply, and the brain must readjust.
The connection between serotonin and akathisia is not fully understood, but research suggests that serotonin exerts inhibitory effects on the dopaminergic pathways involved in motor control and emotional regulation. When serotonin drops rapidly, this inhibitory brake is loosened, dopaminergic activity increases in some regions, and the result can be the restless, agitated state characteristic of akathisia.
The speed of discontinuation matters significantly. Abrupt cessation or rapid dose reduction creates a steep drop in serotonergic signaling, giving the brain little time to compensate. Horowitz and Taylor (2019), in their influential paper in The Lancet Psychiatry, demonstrated that the relationship between antidepressant dose and receptor occupancy is hyperbolic rather than linear. This means that cuts made at low doses have proportionally far greater neurological impact than the same milligram reduction made at higher doses. A drop from 10 mg to 5 mg of an SSRI, for example, produces a much larger change in receptor occupancy than a drop from 40 mg to 35 mg. This pharmacological reality helps explain why akathisia tends to emerge more often in the later stages of tapering or after abrupt discontinuation.
Withdrawal akathisia can be easy to miss because its symptoms overlap with generalized anxiety, panic, and agitation. The key distinguishing feature is the compelling need to move. People with akathisia feel that movement, especially walking or pacing, provides temporary relief from the inner restlessness, even when they know intellectually that they have been walking for an hour and nothing has changed.
Common descriptions from people in antidepressant withdrawal include:
Restlessness deep inside the legs or throughout the body that is not relieved by stretching or position changes. A sense of inner vibration or buzzing. Difficulty sitting still for even a few minutes. Urges to get up and pace during conversations, meals, or at bedtime. An agitation that worsens in the evening (a pattern called nocturnal worsening that is also seen in restless legs syndrome but has a distinct quality in akathisia). Emotional dysphoria, irritability, and a feeling of impending doom that accompanies the physical restlessness.
The emotional component is one reason akathisia is associated with increased suicide risk, a fact documented in early research on antipsychotic-induced akathisia and more recently discussed in the context of antidepressants. The combination of physical discomfort and emotional despair can be overwhelming, particularly for someone who does not know that these symptoms have a name and a mechanism.
Distinguishing akathisia from anxiety is clinically important. Anxiety is primarily an emotional and cognitive state, though it has physical expressions. Akathisia is primarily a movement-urge phenomenon with emotional accompaniments. Asking "do you feel better when you move around?" is a useful question: someone with anxiety may not find that movement relieves it, whereas someone with akathisia typically reports that pacing at least temporarily blunts the inner restlessness.
Not all antidepressants carry equal risk for withdrawal symptoms including akathisia. Several factors determine risk: the medication's half-life, its affinity for serotonin receptors, and how abruptly it is discontinued.
Paroxetine (Paxil/Seroxat) has the shortest half-life among commonly used SSRIs and the highest receptor binding affinity. It is consistently associated with the most severe and rapid-onset withdrawal symptoms, including akathisia. Venlafaxine (Effexor), an SNRI, also has a short half-life and is notorious for producing discontinuation symptoms quickly.
Fluoxetine (Prozac), by contrast, has an extremely long half-life and essentially tapers itself over several weeks, which is why discontinuation symptoms including akathisia are rare with fluoxetine. Sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa) fall in between, with moderate half-lives and moderate discontinuation risk.
SNRIs like duloxetine (Cymbalta) carry high discontinuation risk, partly due to their short half-life and partly due to their dual mechanism affecting both serotonin and norepinephrine. Desvenlafaxine (Pristiq) and levomilnacipran (Fetzima) share similar risks.
The Maudsley Prescribing Guidelines and clinical guidance from the Royal College of Psychiatrists note that discontinuation-related symptoms, including akathisia, are more severe and more common after long-term use, after higher doses, and after rapid reduction or abrupt cessation.
The duration of akathisia from antidepressant withdrawal varies considerably depending on the individual, the medication, the speed of discontinuation, and whether the dose reduction is slowed or stopped.
For most people who experience mild to moderate akathisia during a moderate-pace taper, the symptom stabilizes and then improves over days to a few weeks as the nervous system adjusts to the new dose. If the reduction is held constant, allowing the brain time to adapt, akathisia typically fades within the stabilization window.
For people who have stopped abruptly or whose nervous system is more sensitive to serotonergic changes, akathisia can persist for weeks or, in severe cases, months. This prolonged presentation overlaps with what is now called Prolonged Post-Discontinuation Syndrome, which has received increasing research attention. It is not fully understood why some individuals experience protracted symptoms while others do not, but the severity of the initial reaction, the length of medication use, prior psychiatric history, and genetic factors in serotonin metabolism all appear to play a role.
Returning to the previous dose or a slightly higher dose typically resolves akathisia within days in most cases, which can be both confirming (it identifies the cause) and practically useful for people whose symptoms have become intolerable. A very slow re-taper can then be attempted when the person has stabilized.
There is no single protocol for managing withdrawal akathisia, and what works varies across individuals. The most important intervention is slowing or pausing the taper. Because akathisia is a sign that the nervous system is not tolerating the pace of reduction, continuing to reduce at the same rate is likely to worsen rather than resolve the symptom.
Slowing the taper substantially, often to reductions of 5-10% of the current dose or less, made no more frequently than every four to six weeks, is the approach supported by Horowitz and Taylor's hyperbolic tapering model. Giving the nervous system adequate time to stabilize at each step is protective against akathisia.
Physical movement, paradoxically, can offer temporary relief precisely because akathisia compels movement. Gentle walking, swimming, or other low-intensity movement can interrupt the feedback loop of inner restlessness, at least temporarily. High-intensity exercise sometimes worsens agitation, so calibrating intensity to what feels settling rather than stimulating is important.
Some individuals find that magnesium supplementation, vitamin B6, and propranolol (a beta-blocker used in research on antipsychotic-induced akathisia) provide partial relief. Propranolol in particular has evidence for reducing the subjective distress of akathisia, though its use in withdrawal akathisia specifically has not been studied in controlled trials. Any medication addition during a taper should involve a clinician.
Cold compresses, grounding techniques, and strategies that redirect nervous system activation (such as slow diaphragmatic breathing) can offer short-term relief. These are not cures, but they can reduce the intensity of episodes.
Sleep is frequently disrupted by withdrawal akathisia, particularly the nocturnal worsening pattern. Maintaining a consistent sleep schedule and using supportive interventions (cool rooms, white noise, relaxation practices) can help preserve whatever sleep is accessible during the stabilization period.
Many people find that their prescriber is unfamiliar with akathisia in the context of antidepressant withdrawal. The symptom has historically been discussed more in relation to antipsychotics, and discontinuation symptoms as a broader category remain undertaught in medical training.
Bringing specific language to the appointment helps. Describing the inner restlessness, the urge to move, the temporary relief from pacing, and the time relationship to the dose change all support accurate identification. Mentioning the Barnes Akathisia Rating Scale by name, or referencing published guidance such as the Maudsley Prescribing Guidelines or the Royal College of Psychiatrists' guidance on antidepressant withdrawal, can open a more productive clinical conversation.
The goal of this conversation is not to challenge the prescriber but to ensure that both parties understand what is happening physiologically. A well-informed prescriber can help adjust the taper pace, consider short-term supportive treatments, and monitor the situation appropriately.
Documenting symptoms with a daily journal, noting severity, time of day, and relationship to recent dose changes, creates a record that supports the clinical conversation and helps identify patterns that inform taper adjustments.
No. They can coexist, and they share the surface feature of restlessness, but they are physiologically distinct. Anxiety is primarily cognitive and emotional, driven by activation of stress response pathways. Akathisia is a movement-urge phenomenon rooted in disrupted dopaminergic and serotonergic signaling. The clearest distinguishing feature is that movement temporarily relieves akathisia but does not reliably relieve anxiety. Both can appear in antidepressant withdrawal, and both require attention, but recognizing which is which guides management decisions.
It depends on the severity of the discontinuation and the individual's neurobiology. For mild cases where the taper is slowed appropriately, akathisia often resolves within one to four weeks of holding the dose stable. For people who have stopped abruptly or whose nervous system is highly reactive, it can persist for months. Returning to a stabilizing dose and re-tapering very slowly typically resolves the symptom, though the process requires patience.
Any antidepressant that significantly affects serotonin levels can theoretically produce akathisia on discontinuation, but the risk varies considerably. Short-acting medications with high receptor binding affinity, such as paroxetine and venlafaxine, carry the highest risk. Long-acting medications such as fluoxetine carry the lowest risk. Newer agents like vortioxetine and vilazodone have different receptor profiles and less documented withdrawal experience.
Restless legs syndrome (RLS) involves an urge to move the legs specifically, is worse in the evening and at night, is temporarily relieved by movement, and is associated with a creeping or uncomfortable sensation in the legs. Akathisia can involve the whole body, is not limited to the legs, and is accompanied by a broader inner agitation and emotional dysphoria that is not typically part of RLS. The two conditions can be confused, but RLS is a chronic primary disorder, whereas withdrawal akathisia is a time-limited pharmacological phenomenon.
Slowing the taper reduces the steepness of the neurological drop at each step and gives the brain more time to adapt before the next reduction. Evidence from the hyperbolic tapering research by Horowitz and Taylor (2019) supports that smaller reductions, particularly at lower doses where receptor occupancy changes are proportionally larger, result in fewer and less severe discontinuation symptoms including akathisia. Slower tapering does not guarantee that akathisia will not appear, but it substantially reduces the risk.
Akathisia from antidepressant withdrawal is real, it is recognized in the clinical literature, and it is manageable. The most important response when it appears is to slow down: hold the current dose, give the nervous system time to stabilize, and then consider whether the taper pace needs to be adjusted before moving forward.
If you are navigating this and want support from people who understand it firsthand, taper.community is a forum built for exactly this. Members who have been through akathisia, and the broader experience of tapering antidepressants, share practical knowledge in a space grounded in respect and evidence.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Antidepressant tapering and withdrawal symptom management should be discussed with a qualified healthcare provider. Do not stop or change psychiatric medications without professional guidance.